Research Topic: regulatory approval

Hype or hope? Ketamine for the treatment of depression: results from the application of deep learning to Twitter posts from 2010 to 2023

mycolabadmin

Researchers analyzed over 18,000 Twitter posts from 2010 to 2023 to understand what the public thinks about using ketamine to treat depression. They found that public opinion became much more positive after the FDA approved ketamine as a depression treatment in 2019. Most discussions consisted of personal stories from people who found ketamine helpful, especially those whose depression didn’t respond to other medications. While some people expressed caution and concerns, overall the public seems hopeful about ketamine’s potential.

Read More »

Attitudes toward psychedelics and psychedelic-assisted psychotherapy among Australian mental healthcare providers

mycolabadmin

Australian doctors and mental health professionals have positive views about using psychedelics like psilocybin and MDMA to treat depression and trauma, which were recently approved by regulators. However, many still have safety concerns and gaps in their knowledge, particularly psychiatrists. Most doctors learn about psychedelics from podcasts and websites rather than formal training. The study recommends that professional organizations provide better education to prepare healthcare workers for this new treatment approach.

Read More »

Selective outcome reporting and non-reporting in trials of psychedelic drugs for mental disorders

mycolabadmin

Researchers examined whether studies of three promising psychedelic drugs (esketamine, psilocybin, and MDMA) for treating mental health conditions were reporting their results fairly and completely. They found that nearly 29% of completed trials had no published results, and some studies changed which outcomes they reported on between registration and publication. This selective reporting could make these drugs appear more effective than they actually are.

Read More »

Updated safety evaluation of the food enzyme AMP deaminase from the non‐genetically modified Streptomyces murinus strain AE‐DNTS

mycolabadmin

Scientists evaluated the safety of AMP deaminase, an enzyme used in food processing for yeast and mushroom extract production. The enzyme is produced from a naturally occurring bacterium and is intended to help break down adenosine monophosphate during food manufacturing. Through extensive testing including genetic mutation tests and animal studies, researchers found no safety concerns when used at recommended levels in food processing. The amount of enzyme that consumers might ingest through food is far below levels that could cause any adverse effects.

Read More »
Scroll to Top